Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588656 | 1.00 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| Hydrochloric Acid SCHEMBL588157 | 0.99 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| Hydrochloric Acid SCHEMBL588156 | 0.99 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL4649492 | 0.94 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| Fumaric Acid SCHEMBL587844 | 0.91 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| Fumaric Acid SCHEMBL587845 | 0.91 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| Fumaric Acid SCHEMBL588240 | 0.91 | SLC6A4 (0.67) | SLC6A4SLC6A3SLC6A2CYP2D6ADRB1 | |
| SCHEMBL2951055 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL28761762 | 0.86 | SLC6A4 (0.60) | SLC6A4SLC6A3SLC6A2CYP2D6CETP | |
| SCHEMBL5543652 | 0.86 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
| WO-2009062036-A2 | PROCESSES FOR PREPARING LEVOCETIRIZINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-05-14 | — | — | WO | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
| US-5792770-A | ADMINISTERING AS SEDATIVE, TRANQUILIZER, ANXIOLYTIC AGENT | U C B S.A. (BE) | 1998-08-11 | — | — | US | disclosed |
| US-5792770-A | ADMINISTERING AS SEDATIVE, TRANQUILIZER, ANXIOLYTIC AGENT | U C B S.A. (BE) | 1998-08-11 | — | — | US | disclosed |
| US-5789409-A | ANTIINFLAMMATORY AGENTS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5703082-A | ANTIHISTAMINE; TRANQUILIZERS | U C B S.A. (BE) | 1997-12-30 | — | — | US | disclosed |
| US-5703082-A | ANTIHISTAMINE; TRANQUILIZERS | U C B S.A. (BE) | 1997-12-30 | — | — | US | disclosed |
| US-5698558-A | Methods for treating allergic disorders using optically pure (-) cetirizine | SEPRACOR, INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5683998-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTIPAF AGENTS | TORAY INDUSTRIES, INC. (JP) | 1997-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | SLC6A4 1026/4885SLC6A3 3333/4885SLC6A2 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.